SimBioSys
About SimBioSys
SimBioSys is a pioneering computational oncology company that leverages artificial intelligence (AI) and spatial biophysics to transform cancer care. Their core mission is to individualize therapy and improve patient outcomes by providing clinicians with a deeper, more informed understanding of tumor biology. The company’s technology, including its flagship TumorSight platform, converts standard medical imaging (such as MRI) into AI-powered, decision-driving intelligence. This allows for the creation of spatially resolved virtual replicas, or “digital twins,” of individual tumors and their microenvironments. These digital twins incorporate mechanistic models to simulate key aspects of cancer, including drug sensitivity, delivery, metabolism, and mechanical forces.
For physicians, SimBioSys’s solutions aim to enhance precision medicine by offering tools like TumorSight Viz and TumorSight Risk. TumorSight Viz is an FDA-cleared 3D surgical visualization platform that transforms 2D DCE-MRIs into interactive 3D representations, enabling detailed visualization and analysis of breast cancer for preoperative planning and patient engagement. TumorSight Risk, also FDA-cleared, is an AI-powered, MRI-derived prognostic tool that assesses breast cancer recurrence risk by analyzing routinely collected breast MRI, pathology, and clinical data to generate individualized five- and ten-year prognoses. These tools are designed to provide clear, contextual, and actionable insights, supporting more precise surgical decisions, personalized treatment planning, and a better understanding of disease behavior and prognosis.
Focus Areas
Business Intelligence
| Technology | TumorSight™ Viz, TumorSight™ Risk, TumorScope; combines AI and spatial biophysics, 3D visualization, cloud-based, utilizes NVIDIA A100 Tensor Core GPUs, MONAI and NVIDIA CUDA-X™ libraries |
What Physicians Need to Know
SimBioSys's tools, TumorSight™ Viz and TumorSight® Risk, offer significant advantages for physicians in breast cancer care. TumorSight™ Viz provides interactive 3D visualizations from standard MRI scans, enabling more precise surgical planning by showing tumor volume, distance to key anatomical features, and how the tumor will appear during surgery (prone to supine conversion). This can help in deciding between breast-conserving surgery and mastectomy and enhance patient communication. TumorSight® Risk, an FDA-cleared tool, quickly assesses breast cancer recurrence risk at five and ten years by integrating MRI, pathology, and clinical data, providing actionable insights in hours rather than weeks. This allows for faster, more informed treatment decisions and complements existing diagnostic workflows without requiring additional procedures or specialized hardware. The technology aims to augment, not replace, existing clinical processes, making it a valuable addition to current standards of care.
SimBioSys's TumorSight Viz integrates with standard imaging pipelines, taking routine breast MRIs as input and delivering interactive 3D models without disrupting radiology or surgical workflows. The cloud-based software platform is designed to make results available within standard clinical workflows. They leverage NVIDIA A100 Tensor Core GPUs in the cloud and deploy AI-powered 3D segmentation using MONAI and NVIDIA CUDA-X™ libraries. SimBioSys also collaborates with institutions like Mayo Clinic and UT Southwestern for data analysis and platform expansion. Additionally, they have a strategic distribution agreement with Ricoh 3D for Healthcare to broaden market access to TumorSight™ Viz.
What the Web Says
SimBioSys is a pioneering TechBio company that uses advanced AI and spatial biophysics to revolutionize cancer care. They recently secured FDA clearance for TumorSight® Risk, an AI-powered, MRI-derived breast cancer recurrence risk assessment tool. This software analyzes breast MRI, pathology, and clinical data to provide personalized five- and ten-year recurrence risk insights for women with early-stage breast cancer. While there is significant news coverage about their product advancements and FDA clearances, comprehensive product and employer reviews on platforms like G2, Glassdoor, Capterra, and Reddit are limited or refer to other companies with similar names.
Overall: MixedStrengths
- FDA-cleared AI-powered software for breast cancer recurrence risk assessment (TumorSight® Risk).
- Combines breast MRI, pathology, and clinical data for personalized prognoses.
- Results available before surgery, eliminating the need for additional procedures or tissue shipment.
- Expands the TumorSight platform from surgical visualization into prognostic intelligence.
- Potential to provide more individualized care for patients.
- Strong focus on innovation in cancer care with AI and spatial biophysics.
Limitations
- Limited readily available product reviews on major platforms like G2, Capterra, and Glassdoor specifically for SimBioSys (the cancer care company).
- Confusion with other companies named 'Symbiosis' or 'Simbionix' in search results, making it difficult to isolate relevant reviews.
- No specific employer reviews found for SimBioSys (the cancer care company) on Glassdoor or Indeed, only for similarly named entities.
- Some Reddit discussions about 'Symbiosis' refer to a coaching institute or university with negative feedback, which is not relevant to SimBioSys.
- G2 reviews for 'Simbionix Medical Simulation' mention high setup cost and complicated technical requirements, but it's unclear if this is the same company.
Based on reviews from: AuntMinnie, SimplyHired, PR Newswire, MPO (Medical Product Outsourcing), Reddit, Indeed.com, G2, Capterra
Last updated: 2026-10-18
Videos
News, demos, and interviews about SimBioSys.
Videos load interactively. If none appear, search YouTube for SimBioSys →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded SimBioSys.
Comparisons
Related Companies
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]
Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]
Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]
Surgical Reality is a healthcare AI company that specializes in advanced AI-powered 3D medical imaging and surgical planning software for thoracic surgery. Their core product, the Surgical Reality Viewer, converts standard CT scans into high-fidelity, patient-specific 3D models of the entire lung within minutes. This technology is designed to assist trained healthcare professionals with preoperative […]